Executive Summary of 2025 International Conference of the Korean Dementia Association and International Congress of the Asian Society Against Dementia (IC-KDA/ASAD 2025): A Report From the Academic Committee of the Korean Dementia Association.
| Title: | Executive Summary of 2025 International Conference of the Korean Dementia Association and International Congress of the Asian Society Against Dementia (IC-KDA/ASAD 2025): A Report From the Academic Committee of the Korean Dementia Association. |
|---|---|
| Authors: | Kim J; Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.; Kim GH; Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University, College of Medicine, Seoul, Korea.; Kang K; Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea.; Kim HJ; Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Suh J; Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea.; Yoon B; Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Cho H; Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Pyun JM; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.; Park YH; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.; Choe HK; Department of Brain Sciences, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu, Korea.; Kim YK; Brain Science Institute, Korea Institute of Science and Technology, Seoul, Korea.; Lee KH; Department of Biomedical Science, Chosun University, Gwangju, Korea.; Kim JG; Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Korea.; Yang SJ; Department of Neurology, Severance Hospital of Yonsei University Health System, Seoul, Korea.; Baek MJ; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.; Chin J; Department of Psychology, College of Social Sciences, Hallym University, Chuncheon, Korea.; Jang H; Department of Neurology, Asan Medical Center, Seoul, Korea.; Moon SY; Department of Neurology, Ajou University School of Medicine, Suwon, Korea. |
| Corporate Authors: | Academic Committee of the Korean Dementia Association |
| Source: | Dementia and neurocognitive disorders [Dement Neurocogn Disord] 2025 Oct; Vol. 24 (4), pp. 209-232. Date of Electronic Publication: 2025 Oct 20. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Korean Dementia Association Country of Publication: Korea (South) NLM ID: 101600298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2384-0757 (Electronic) Linking ISSN: 17381495 NLM ISO Abbreviation: Dement Neurocogn Disord Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Seoul, Korea : Korean Dementia Association |
| Abstract: | The International Conference of the Korean Dementia Association (IC-KDA) 2025 was held jointly with the 19th International Congress of the Asian Society Against Dementia (ASAD) in Seoul, South Korea (May 8-10, 2025), under the theme "Breaking Barriers of Dementia: From Research to Real-world Practice." The program opened with a Pre-Conference Symposium on "Dementia Treatment Update: Lecanemab and NPH" featuring 14 speakers, followed by the main meeting comprising 3 plenary sessions (5 speakers), 7 luncheon-symposium presentations, 16 parallel symposia (48 speakers), a special symposium (2 speakers), and 4 oral-presentation sessions (20 presenters). The congress was attended by 1,052 participants from 27 countries and included 213 poster presentations. Scientific highlights spanned the continuum from discovery to implementation: plasma and imaging biomarkers, retinal and electroencephalogram/voice-based digital biomarkers, and multimodal neuroimaging for risk stratification and outcome prediction; updates on anti-amyloid monoclonal antibodies (MABs) (lecanemab, donanemab), safety/amyloid-related imaging abnormalities management, and real-world data frameworks; mechanistic and multi-omics insights (genetics, metabolomics, epigenomics, transcriptomics); neuroinflammation and glia-mediated pathways; young-onset dementia cohorts across Asia-Pacific; vascular cognitive impairment trials and pathophysiology; neuropsychiatric symptoms and evidence-based behavioral and psychological symptoms of dementia care; lifestyle and multidomain prevention (Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay-based interventions); dementia-friendly communities and caregiver support; and emerging neuromodulation modalities (low-intensity ultrasound, photobiomodulation, vagus nerve stimulation). Together, the joint IC-KDA & ASAD 2025 meeting emphasized precision medicine and implementation science, bridging laboratory advances with clinical practice and health-system delivery to improve outcomes for people living with dementia and their caregivers.; (© 2025 Korean Dementia Association.) |
| Competing Interests: | Conflict of Interest: The authors have no financial conflicts of interest. |
| References: | Alzheimers Dement. 2025 Feb;21(2):e14437. (PMID: 39711521); Nature. 2016 Dec 7;540(7632):230-235. (PMID: 27929004); IEEE J Biomed Health Inform. 2022 Aug;26(8):3697-3707. (PMID: 35511844); Stem Cell Reports. 2025 Jan 14;20(1):102372. (PMID: 39642875); Transl Neurodegener. 2021 Dec 7;10(1):48. (PMID: 34872618); Nat Commun. 2023 Feb 13;14(1):802. (PMID: 36781874); J Prev Alzheimers Dis. 2025 May;12(5):100098. (PMID: 40102145); Alzheimers Dement. 2024 Nov;20(11):7686-7697. (PMID: 39254221); Alzheimers Dement. 2024 Aug;20(8):5143-5169. (PMID: 38934362); EBioMedicine. 2024 Apr;102:105082. (PMID: 38531174); East Asian Arch Psychiatry. 2010 Dec;20(4):163-8. (PMID: 22348924); BMJ. 2024 Mar 21;384:e077764. (PMID: 38514079); Front Public Health. 2021 May 14;9:628700. (PMID: 34055712); Nat Med. 2023 Sep;29(9):2224-2232. (PMID: 37653343); Int J Mol Sci. 2019 Mar 26;20(6):. (PMID: 30917570); Alzheimers Dement (N Y). 2020 May 27;6(1):e12033. (PMID: 32490143); J Gerontol A Biol Sci Med Sci. 2020 Mar 9;75(4):631-639. (PMID: 30346494); World Neurosurg. 2023 Aug;176:e427-e437. (PMID: 37245671); Nat Commun. 2022 Apr 13;13(1):1972. (PMID: 35418126); Aging (Albany NY). 2021 Jun 18;13(12):15898-15916. (PMID: 34148030); Neuroimage. 2019 Feb 1;186:690-702. (PMID: 30503934); Alzheimers Dement. 2025 Mar;21(3):e14566. (PMID: 40042459); Fluids Barriers CNS. 2022 Sep 1;19(1):66. (PMID: 36045420); Dement Neurocogn Disord. 2024 Oct;23(4):165-187. (PMID: 39512702); Lancet Neurol. 2015 Jun;14(6):585-94. (PMID: 25934242); Alzheimers Dement. 2024 Jan;20(1):243-252. (PMID: 37563770); BMC Geriatr. 2021 Apr 7;21(1):230. (PMID: 33827446); Alzheimers Dement. 2025 Feb;21(2):e14473. (PMID: 39732514); Sci Rep. 2021 Aug 26;11(1):17255. (PMID: 34446742) |
| Contributed Indexing: | Keywords: Alzheimer Disease; Biomarkers; Dementia; Neuroimaging; Neuroinflammation; Vascular Cognitive Impairment |
| Entry Date(s): | Date Created: 20251112 Date Completed: 20251112 Latest Revision: 20251114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12599462 |
| DOI: | 10.12779/dnd.2025.24.4.209 |
| PMID: | 41220866 |
| Database: | MEDLINE |
Journal Article; Review